ACR 2026 RheumNow Lupus Topic Compilation b Save
Lupus Control without Steroid Burden
The Lupus Outcomes Gap
Block the Antibody Lupus, Myositis, Scleroderma
Proteinuria Another one bites the dust in lupus nephritis
Tirzepitide Add on or start together in PsA
Does the Air we Breathe Shape Lupus
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to roomnow.live to see the full program and register today.
Hi, everyone. I'm Melissa Axelrod, a rheumatology fellow at Columbia reporting from room now from ACR convergence twenty twenty six. So today I'm going to discuss abstract two seventy three which examines glucocorticoid reduction with obinutuzumab in the phase three ALLOGORY trial. We know that one of our big challenges in treating lupus is achieving disease control while minimizing chronic steroid use. ALLOGORY demonstrated significant improvements in disease activity with obinutuzumab compared with placebo.
Both added to standard therapy. This analysis specifically looked at whether patients could achieve more ambitious glucocorticoid targets. Among patients entering the trial on at least ten mg of prednisone daily, approx. Seventy three percent receiving obinutuzumab maintained a dose of five mg or less between weeks forty and fifty two compared to forty nine percent receiving placebo. And approximately twenty one percent of obinutuzumab treated patients were completely off glucocorticoids at week fifty two compared with eleven percent receiving placebo.
So what do I find particularly compelling about this story? First, I like that we're moving beyond composite disease activity scores and focusing on outcomes that matter for long term patient health. Our treatment goal isn't simply to control inflammation, it's to do so without exposing patients to year long glucocorticoid related morbidity. Second, the sustained reduction to five milligrams or less was pre specified endpoint and the randomized trial design strengthens confidence that obinutuzumab contributed to the improvement. And importantly, the parent trial also demonstrated improvements in low disease activity remission and FLAIR outcomes.
But I think there are some limitations worth emphasizing. The more stringent outcomes including complete steroid discontinuation were exploratory and assessed as a single time point. And even with abinutuzumab nearly eighty percent of patients weren't completely off steroids by week fifty two. The trial was also used protocol directed tapering and it didn't specifically guide patients towards complete steroid elimination. So I wonder whether a more structured taper to zero strategy might produce different results.
So what's my clinical takeaway? I think these findings reinforce that steroid sparing should be a meaningful measure of therapeutic success rather than just an added benefit. Ebenetuzumab appears promising in helping patients achieve disease control with less prednisolone. But I think the bigger goal remains sustained steroid free remission and we're not there yet.
Hi. My name is Al Kim. I'm in Orlando, Florida for the twenty twenty six ACR Convergence Conference, and we're covering some more topics within lupus. This one is about poster abstracts that have been revealing the gaps in outcomes. Not the gaps in terms of the clinical outcomes that we report in clinical trials, but the outcomes that the patients really care about, the patient report outcomes.
So it's interesting because the immunology we've been having has never been better and we've had more approved drugs in lupus than before. But again, the patients aren't necessarily feeling any better. So let's start with cardiovascular risk. Abstract nine twenty two looked at coronary artery calcification in patients with lupus where the ACCAHA prevent calculator actually predicted them to be low risk. So these are low risk patients using the prevent calculator, but they had their calcium score checked.
Guess what? They were highly discordant. The majority of these patients had high calcium scores despite the fact that the prevent calculator dictated that or told them that they should be low risk. I think this is a really interesting lesson about tools that are developed for the general population that are applied in disease specific populations such as lupus, and you're starting to see some discordances there. Then let's look at the kidney.
Let's focus on abstracts eighteen sixty four and eighteen sixty five. The first one is transplant access amongst patients with end stage kidney disease and patients with lupus. And the second one is graft failure in those recipients compared to other immune mediated diseases. One of them is about getting people into the door, the other one is what happens after you do. And the story for both is bleak.
We spent fifteen years optimizing induction therapies for lupus nephritis, but these two abstracts are about patients for whom that optimization did not work and that population has not and will not go away. Then there's abstract nine twenty four. This is the one that I was most interested in, because they looked at longitudinal cognitive performance and tried to understand risk factors for the greatest cognitive impairment. Guess what that risk factor was? It was actually anxiety, not disease activity, not damage, not glucocorticoid exposure, anxiety.
So sure, you know, this is just an association. So the overread is going to be direction and causality. But it's also only the variable on the list that we actually can modify, potentially modify, and most of us aren't screening for it. So you put these together and a pattern shows up. Every one of these risk instruments was built somewhere else and imported.
We keep losing kidneys, cognition, potentially jobs while the serologies improve. And the reason we are surprised every time is because we're using these borrowed instruments.
Hi, I'm Andrea Fava coming to you from ACR in Orlando. And today I want to tell you about something that I've learned on day one that I found particularly interesting. I'm going to tell you about lupus but let me start from myositis. Andy Mammen from the NIH presented beautiful data about this concept of autoantibodies getting into the cells. What?
We didn't expect that, right? We have learned that antibodies, they are humoral substances. They act on the outside of cells. Well, turns out that if you look very carefully, these antibodies can get inside the cells. And Andy Mammond showed beautiful data that in myositis, he found autoantibody specifically getting inside muscle cells and causing trouble, they can bind to their target, they can inactivate them, it can cause some signature that can be recapitulated and eventually they seem to be implicated in disease.
Now why is this relevant? Well, let me tell you a second story now about scleroderma. There was a plenary session yesterday that was after eight seventy where they looked at patients with scleroderma with antibody against SCL70, topoisomerase one, and again they found them inside the cells in the skin and these antibodies could also cause some issues. What's interesting is that when we ask how does antibody get into the cell, well they get in, by endosomes, and it seems that the FcRn, so the neonatal Fc receptor that can capture antibody and brings them in, is implicated. And why is that important?
Because you can block it. These antibodies may be pathogenic and we have now an agent that can block that. So I'll get to the Nipocalimab Abstract eight seventy five, a phase two fifty two weeks randomized controlled trial, placebo controlled and blinded in lupus nephritis of this agent, pipocalimab, that blocks FcRn, which blocks the recycling of IgGs. So the IgGs that we have, they don't get cell degenerative, they get lost. And what they've shown in this trial with seventy five patients per arm, three arms total, so placebo, low dose, high dose of the drug, they had beautiful responses with, a SRI four response of fifty three percent versus thirty nine percent, the high dose versus the placebo, at twenty four weeks maintained at one year.
The joint count dropped already at four weeks, so blocking the antibodies acts very fast. What was interesting is that if you look at the subset that was antibody positive, the delta between drug and placebo was higher and the smaller subset with the super high antibody, the delta was massive, 67. So very exciting data, very exciting mechanism and if you want to learn more go on rheumnow.com. Hi, I'm Andrea Fava coming to you from Orlando at ACR twenty twenty six, and I wanted to speak to you about proteinuria and lupus nephritis. Now proteinuria has been taking a lot of punches in the last few years, being an unreliable way to assess response to treatment.
But boy, this study is trying to really put the final nail in the coffin. So presented by Ioannis Peyrodis, this is part of ReBioloop. This is a trial in which patients with lupus nephritis have a biopsy baseline and then they get randomized to have a per protocol repeat biopsy after one year. And what he looked at is does proteinuria at one year associate with the histologic remission of lupus nephritis and what he found as we expected is that it does not. One in four patients had discordance between proteinuria and histologic activity.
I'll give you some numbers. These were eighty three patients who got the repeat biopsy and of patients who achieved this proteinuria below 500 which is our complete response rate, fifteen percent had an activity index greater than four and seven out of the twelve patients who had high activity in the biopsy were classified as complete responders by proteinuria. In total it was one in four patients who has been misclassified. He then looked at what could be a threshold for proteinuria that can truly help us identify who has responded to treatment based on a reduction of inflammation in the biopsy, which is what we care about because we want to remove this inflammation to protect the kidneys. He found that a threshold of 0.2 of proteinuria at one ear, so deep remission, was associated with an interesting separation, but the separation is not in a good way.
Let me tell you, if you have at one ear a proteinuria above 0.2, there was no chance that you were in remission. So if you were at 0.3, 0.4, 0.5, there was zero chance or maybe a one percent chance that you were in histologic remission with an activity index of zero. On the contrary, if you had the proteinuria below 0.2, this is when we are super happy in clinic, there was only a fifty percent chance that you were in histologic remission. So I think that the authors are trying to completely trash the use of proteinuria here. I think there may be a little bit of a leeway, but this study is truly challenging our belief in proteinuria and is truly highlighting the need either for repeat biopsies, a patient not particularly like getting a big needle in the back every so often, but definitely the need of better biomarkers and us being very cognizant about how we interpret proteinuria and lupus nephritis.
If you want to learn more, go on roomnow.com.
Welcome back. This is Jeehali reporting for RheumNow for ACR twenty twenty six in Orlando. In an earlier video, I discussed the Together PSA study, which looked at combining tirzepatide and ezikizumab together from the get go. And the results were promising. There was improvement in outcomes in terms of disease activity as well as objective measures of tender joint pain and swollen joint pain.
But the reality is in a lot of our patients, we often don't have the opportunity to start medications together, perhaps for insurance reasons, preferences, or wanting to ensure that our patients are not exposed to drug drugs and not being able to separate out adverse effects. So question is, is it still effective when you add on these medications later on? And two abstracts allude to that and may give us answers. The first one, Abstract three forty four, is actually a derivative of the TOGETHER study and they're calling it the TOGETHER Amplify. And this is just a design abstract, so I'm just giving you a glimpse into it because hopefully by ACR twenty twenty seven, we'll have some answers.
So this is a phase four study, a single arm, open label extension, where they are aiming to enroll about 200 patients. And whereas the together started as ekizumab and tirzepatide together, this time they're looking to add it on within the first three months, but no later than four months. So it's getting at the question, if you add on a GLP one later in patients who are already treated, do you get the same benefit? Now I think one thing is, again, the three months is still early on where the drug may still getting effective in terms of biologic exposure, and it may be challenged to separate, whether there is a difference. But I think what I love about this is that it is a more realistic representation of how we're probably going to approach prescribing these medications.
So there's more to come on this. And interestingly, we may have a little bit of a glimpse that that study itself may be promising. And this is coming from abstract number zero three four six. Mind you, this is also a prospective ongoing trial and this is just the preliminary data where there's only 15 patients. However, what it's showing, and it's a little bit different, is this is patients who can be on any and every biologic, so not just izikizumab.
So it'll be interesting to see if there's differences based on the type of biologics there are, but it is adding on patients who have been on stable treatment for at least three months. And it'll be interesting to see how that variance of treatment comes in as they have more data. But then they are adding on the tirzepatide later. And what they're showing is that, yes, there's improvement, but in addition to the objective measures of disease activity, they are looking at pain and fatigue. So residual symptoms and also subjective symptoms that affect our patients in terms of how they live with these diseases on a day to day basis.
So some early signs of promise depending on whether you add it on from the get go or later on. So three questions. Do you add it on early? Can you add it on later? And along with disease activity, does it help with other symptoms?
So more to look out for and I welcome coming back to find those results later on. Again, thank you for listening. This is Jeehaw Lee for RheumNow.
Hi. This is Bella Mehta from RheumNow reporting from ACR twenty twenty six, and I came across a very interesting abstract. It's zero nine two zero. And what it's looking at is does our air quality or the air we breathe affect lupus? So I've been interested in AQI or air quality index because you hear it in the news, you see it in the New York Times, and what you see is even when you check the weather, AQI is something that is...
Pops up on my phone. So these investigators did a very, very well... Well defined study using the market scan dataset, did around a decade or so of follow-up data, and had patients with lupus or were trying to figure out if air quality affects incidence of lupus. And what they... They measured two things.
It was median AQI or air quality index and also unhealthy air. And what they found was that... Again, this was a large study with around twenty one thousand SLE patients. So pretty robust sample size. They're looking at an environmental exposure, which is related to where they live.
And what they found was that for every 10 units increase in median AQI, there was a two percent higher risk for lupus. Also, every one percent increase in unhealthy air, there was a four percent increase in lupus incidence. Now... So now we know that lupus activity does, get worse with bad air. This is also incidence of lupus.
But, again, the caveat here is that it's an observational study. So all we know is this association. And maybe what they're capturing from the environmental exposure is the area that they live in, and there's many other factors that go into where a person lives. So maybe it's completely confounded by other factors within that area that they live in. But I think the biggest take home point that I see here is their environmental exposures are potentially causing some problems within our diseases and are potentially modifiable.
And and maybe because of my... The way I see it from my angle of disparities literature, maybe AQI is a is a indicator of some sort of social disadvantage that people living in those areas have. And it's it's not just an environmental lupus study, that's why, but it's also a lupus disparity study. And we need to start talking about this more within the community because I know patients are asking about these things. So I like the study.
It's very well done. And, again, my biggest take home is that air quality does matter to an extent. So with that, follow me more on RheumNow and Twitter at Bella underscore Mehta. Thank you.
Go to roomnow.live to see the full program and register today.
Hi, everyone. I'm Melissa Axelrod, a rheumatology fellow at Columbia reporting from room now from ACR convergence twenty twenty six. So today I'm going to discuss abstract two seventy three which examines glucocorticoid reduction with obinutuzumab in the phase three ALLOGORY trial. We know that one of our big challenges in treating lupus is achieving disease control while minimizing chronic steroid use. ALLOGORY demonstrated significant improvements in disease activity with obinutuzumab compared with placebo.
Both added to standard therapy. This analysis specifically looked at whether patients could achieve more ambitious glucocorticoid targets. Among patients entering the trial on at least ten mg of prednisone daily, approx. Seventy three percent receiving obinutuzumab maintained a dose of five mg or less between weeks forty and fifty two compared to forty nine percent receiving placebo. And approximately twenty one percent of obinutuzumab treated patients were completely off glucocorticoids at week fifty two compared with eleven percent receiving placebo.
So what do I find particularly compelling about this story? First, I like that we're moving beyond composite disease activity scores and focusing on outcomes that matter for long term patient health. Our treatment goal isn't simply to control inflammation, it's to do so without exposing patients to year long glucocorticoid related morbidity. Second, the sustained reduction to five milligrams or less was pre specified endpoint and the randomized trial design strengthens confidence that obinutuzumab contributed to the improvement. And importantly, the parent trial also demonstrated improvements in low disease activity remission and FLAIR outcomes.
But I think there are some limitations worth emphasizing. The more stringent outcomes including complete steroid discontinuation were exploratory and assessed as a single time point. And even with abinutuzumab nearly eighty percent of patients weren't completely off steroids by week fifty two. The trial was also used protocol directed tapering and it didn't specifically guide patients towards complete steroid elimination. So I wonder whether a more structured taper to zero strategy might produce different results.
So what's my clinical takeaway? I think these findings reinforce that steroid sparing should be a meaningful measure of therapeutic success rather than just an added benefit. Ebenetuzumab appears promising in helping patients achieve disease control with less prednisolone. But I think the bigger goal remains sustained steroid free remission and we're not there yet.
Hi. My name is Al Kim. I'm in Orlando, Florida for the twenty twenty six ACR Convergence Conference, and we're covering some more topics within lupus. This one is about poster abstracts that have been revealing the gaps in outcomes. Not the gaps in terms of the clinical outcomes that we report in clinical trials, but the outcomes that the patients really care about, the patient report outcomes.
So it's interesting because the immunology we've been having has never been better and we've had more approved drugs in lupus than before. But again, the patients aren't necessarily feeling any better. So let's start with cardiovascular risk. Abstract nine twenty two looked at coronary artery calcification in patients with lupus where the ACCAHA prevent calculator actually predicted them to be low risk. So these are low risk patients using the prevent calculator, but they had their calcium score checked.
Guess what? They were highly discordant. The majority of these patients had high calcium scores despite the fact that the prevent calculator dictated that or told them that they should be low risk. I think this is a really interesting lesson about tools that are developed for the general population that are applied in disease specific populations such as lupus, and you're starting to see some discordances there. Then let's look at the kidney.
Let's focus on abstracts eighteen sixty four and eighteen sixty five. The first one is transplant access amongst patients with end stage kidney disease and patients with lupus. And the second one is graft failure in those recipients compared to other immune mediated diseases. One of them is about getting people into the door, the other one is what happens after you do. And the story for both is bleak.
We spent fifteen years optimizing induction therapies for lupus nephritis, but these two abstracts are about patients for whom that optimization did not work and that population has not and will not go away. Then there's abstract nine twenty four. This is the one that I was most interested in, because they looked at longitudinal cognitive performance and tried to understand risk factors for the greatest cognitive impairment. Guess what that risk factor was? It was actually anxiety, not disease activity, not damage, not glucocorticoid exposure, anxiety.
So sure, you know, this is just an association. So the overread is going to be direction and causality. But it's also only the variable on the list that we actually can modify, potentially modify, and most of us aren't screening for it. So you put these together and a pattern shows up. Every one of these risk instruments was built somewhere else and imported.
We keep losing kidneys, cognition, potentially jobs while the serologies improve. And the reason we are surprised every time is because we're using these borrowed instruments.
Hi, I'm Andrea Fava coming to you from ACR in Orlando. And today I want to tell you about something that I've learned on day one that I found particularly interesting. I'm going to tell you about lupus but let me start from myositis. Andy Mammen from the NIH presented beautiful data about this concept of autoantibodies getting into the cells. What?
We didn't expect that, right? We have learned that antibodies, they are humoral substances. They act on the outside of cells. Well, turns out that if you look very carefully, these antibodies can get inside the cells. And Andy Mammond showed beautiful data that in myositis, he found autoantibody specifically getting inside muscle cells and causing trouble, they can bind to their target, they can inactivate them, it can cause some signature that can be recapitulated and eventually they seem to be implicated in disease.
Now why is this relevant? Well, let me tell you a second story now about scleroderma. There was a plenary session yesterday that was after eight seventy where they looked at patients with scleroderma with antibody against SCL70, topoisomerase one, and again they found them inside the cells in the skin and these antibodies could also cause some issues. What's interesting is that when we ask how does antibody get into the cell, well they get in, by endosomes, and it seems that the FcRn, so the neonatal Fc receptor that can capture antibody and brings them in, is implicated. And why is that important?
Because you can block it. These antibodies may be pathogenic and we have now an agent that can block that. So I'll get to the Nipocalimab Abstract eight seventy five, a phase two fifty two weeks randomized controlled trial, placebo controlled and blinded in lupus nephritis of this agent, pipocalimab, that blocks FcRn, which blocks the recycling of IgGs. So the IgGs that we have, they don't get cell degenerative, they get lost. And what they've shown in this trial with seventy five patients per arm, three arms total, so placebo, low dose, high dose of the drug, they had beautiful responses with, a SRI four response of fifty three percent versus thirty nine percent, the high dose versus the placebo, at twenty four weeks maintained at one year.
The joint count dropped already at four weeks, so blocking the antibodies acts very fast. What was interesting is that if you look at the subset that was antibody positive, the delta between drug and placebo was higher and the smaller subset with the super high antibody, the delta was massive, 67. So very exciting data, very exciting mechanism and if you want to learn more go on rheumnow.com. Hi, I'm Andrea Fava coming to you from Orlando at ACR twenty twenty six, and I wanted to speak to you about proteinuria and lupus nephritis. Now proteinuria has been taking a lot of punches in the last few years, being an unreliable way to assess response to treatment.
But boy, this study is trying to really put the final nail in the coffin. So presented by Ioannis Peyrodis, this is part of ReBioloop. This is a trial in which patients with lupus nephritis have a biopsy baseline and then they get randomized to have a per protocol repeat biopsy after one year. And what he looked at is does proteinuria at one year associate with the histologic remission of lupus nephritis and what he found as we expected is that it does not. One in four patients had discordance between proteinuria and histologic activity.
I'll give you some numbers. These were eighty three patients who got the repeat biopsy and of patients who achieved this proteinuria below 500 which is our complete response rate, fifteen percent had an activity index greater than four and seven out of the twelve patients who had high activity in the biopsy were classified as complete responders by proteinuria. In total it was one in four patients who has been misclassified. He then looked at what could be a threshold for proteinuria that can truly help us identify who has responded to treatment based on a reduction of inflammation in the biopsy, which is what we care about because we want to remove this inflammation to protect the kidneys. He found that a threshold of 0.2 of proteinuria at one ear, so deep remission, was associated with an interesting separation, but the separation is not in a good way.
Let me tell you, if you have at one ear a proteinuria above 0.2, there was no chance that you were in remission. So if you were at 0.3, 0.4, 0.5, there was zero chance or maybe a one percent chance that you were in histologic remission with an activity index of zero. On the contrary, if you had the proteinuria below 0.2, this is when we are super happy in clinic, there was only a fifty percent chance that you were in histologic remission. So I think that the authors are trying to completely trash the use of proteinuria here. I think there may be a little bit of a leeway, but this study is truly challenging our belief in proteinuria and is truly highlighting the need either for repeat biopsies, a patient not particularly like getting a big needle in the back every so often, but definitely the need of better biomarkers and us being very cognizant about how we interpret proteinuria and lupus nephritis.
If you want to learn more, go on roomnow.com.
Welcome back. This is Jeehali reporting for RheumNow for ACR twenty twenty six in Orlando. In an earlier video, I discussed the Together PSA study, which looked at combining tirzepatide and ezikizumab together from the get go. And the results were promising. There was improvement in outcomes in terms of disease activity as well as objective measures of tender joint pain and swollen joint pain.
But the reality is in a lot of our patients, we often don't have the opportunity to start medications together, perhaps for insurance reasons, preferences, or wanting to ensure that our patients are not exposed to drug drugs and not being able to separate out adverse effects. So question is, is it still effective when you add on these medications later on? And two abstracts allude to that and may give us answers. The first one, Abstract three forty four, is actually a derivative of the TOGETHER study and they're calling it the TOGETHER Amplify. And this is just a design abstract, so I'm just giving you a glimpse into it because hopefully by ACR twenty twenty seven, we'll have some answers.
So this is a phase four study, a single arm, open label extension, where they are aiming to enroll about 200 patients. And whereas the together started as ekizumab and tirzepatide together, this time they're looking to add it on within the first three months, but no later than four months. So it's getting at the question, if you add on a GLP one later in patients who are already treated, do you get the same benefit? Now I think one thing is, again, the three months is still early on where the drug may still getting effective in terms of biologic exposure, and it may be challenged to separate, whether there is a difference. But I think what I love about this is that it is a more realistic representation of how we're probably going to approach prescribing these medications.
So there's more to come on this. And interestingly, we may have a little bit of a glimpse that that study itself may be promising. And this is coming from abstract number zero three four six. Mind you, this is also a prospective ongoing trial and this is just the preliminary data where there's only 15 patients. However, what it's showing, and it's a little bit different, is this is patients who can be on any and every biologic, so not just izikizumab.
So it'll be interesting to see if there's differences based on the type of biologics there are, but it is adding on patients who have been on stable treatment for at least three months. And it'll be interesting to see how that variance of treatment comes in as they have more data. But then they are adding on the tirzepatide later. And what they're showing is that, yes, there's improvement, but in addition to the objective measures of disease activity, they are looking at pain and fatigue. So residual symptoms and also subjective symptoms that affect our patients in terms of how they live with these diseases on a day to day basis.
So some early signs of promise depending on whether you add it on from the get go or later on. So three questions. Do you add it on early? Can you add it on later? And along with disease activity, does it help with other symptoms?
So more to look out for and I welcome coming back to find those results later on. Again, thank you for listening. This is Jeehaw Lee for RheumNow.
Hi. This is Bella Mehta from RheumNow reporting from ACR twenty twenty six, and I came across a very interesting abstract. It's zero nine two zero. And what it's looking at is does our air quality or the air we breathe affect lupus? So I've been interested in AQI or air quality index because you hear it in the news, you see it in the New York Times, and what you see is even when you check the weather, AQI is something that is...
Pops up on my phone. So these investigators did a very, very well... Well defined study using the market scan dataset, did around a decade or so of follow-up data, and had patients with lupus or were trying to figure out if air quality affects incidence of lupus. And what they... They measured two things.
It was median AQI or air quality index and also unhealthy air. And what they found was that... Again, this was a large study with around twenty one thousand SLE patients. So pretty robust sample size. They're looking at an environmental exposure, which is related to where they live.
And what they found was that for every 10 units increase in median AQI, there was a two percent higher risk for lupus. Also, every one percent increase in unhealthy air, there was a four percent increase in lupus incidence. Now... So now we know that lupus activity does, get worse with bad air. This is also incidence of lupus.
But, again, the caveat here is that it's an observational study. So all we know is this association. And maybe what they're capturing from the environmental exposure is the area that they live in, and there's many other factors that go into where a person lives. So maybe it's completely confounded by other factors within that area that they live in. But I think the biggest take home point that I see here is their environmental exposures are potentially causing some problems within our diseases and are potentially modifiable.
And and maybe because of my... The way I see it from my angle of disparities literature, maybe AQI is a is a indicator of some sort of social disadvantage that people living in those areas have. And it's it's not just an environmental lupus study, that's why, but it's also a lupus disparity study. And we need to start talking about this more within the community because I know patients are asking about these things. So I like the study.
It's very well done. And, again, my biggest take home is that air quality does matter to an extent. So with that, follow me more on RheumNow and Twitter at Bella underscore Mehta. Thank you.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.